Annual Congress European Association of Urology: highlights in Stockholm

December 18, 2008

The 24th Annual Congress of the European Association of Urology (EAU) will be held from 17 to 21 March 2009 in the Stockholm International Fairs (SE). The scientific programme covers the whole range of the urological field. From 'Bladder Unlimited' to 'The art of ageing'; it will all be discussed at the congress.

The traditional half-day joint sessions with regional urological groups are extended to a full-day event called EAU International Day - Urology Beyond Europe.

In Stockholm the EAU expects an estimated 10,000 delegates and 3,000 exhibitors.

The EAU aims to present the best of scientific results, lectures and educational courses. This year's programme has a new dimension with an additional congress day on Tuesday 17 March. This day, entitled 'Urology Beyond Europe' endeavours to intensify the collaboration between the EAU and urological societies worldwide. Included in the programme are international joint sessions and case discussions covering selected urological topics.

Second-day highlights include the meetings of the EAU Section Office, with 14 offices and EAU-affiliated groups simultaneously holding their sessions. The section office meetings annually showcase the latest research projects and initiatives which focus on specialised fields such as uro-technology, female and functional urology, transplantation, andrology and urological imaging. 'Bladder Unlimited' is the focus of the European Society of Urological Technology (ESUT). The ESUT will be presenting live robotic surgery for the first time. Collaborating with the prestigious Karolinska Hospital in Stockholm, procedures such as laparoscopic and robotic cystectomies and robotic bladder surgery will be demonstrated..

From the European Society of Andrological Urology (ESAU), expert lectures and roundtable discussion will revolve on the theme 'Testosterone and the Art of Ageing'. The manifold issues related to testosterone will be linked to discussions on endothelial cell, germ cell and other aspects in the molecular level.

In response to feedback from EAU members, the sub-plenary sessions have scheduled two separate meetings on the topics of infections (chaired by Prof. Truls Erik Bjerklund Johansen (DK)) and testis/penile cancer (chaired by Prof. Peter Albers (DE)). The latter meeting will discuss techniques in organ-sparing surgery and the latest updates on chemo and radiation therapy for testis cancer.

Third-day sessions will highlight current challenges in urology starting with a plenary session on the evolution of new technologies and treatments with particular emphasis on Benign Prostatic Hyperplasia (BPH), including guest lecturers from the Pan African Urological Surgeon's Association (PAUSA). Dr. Michael Chancellor (Detroit, USA) will give the AUA lecture entitled 'Botulinum toxin for the lower urinary tract- past, present and future.'

On Day 4, the morning plenary sessions will focus on hot topics in prostate cancer. Providing the SIU lecture is Dr. Martin Gleave (Vancouver, Canada) who will discuss castration resistant prostate cancer with emphasis on new therapeutic approaches. Sub-plenary sessions will continue in the afternoon meetings focusing on andrology, basic science (oncology) and reconstruction.

The last day plenary session on Saturday, 21 March 2009, pays special attention to bladder cancer with guest lecturers and expert speakers taking up manifold issues and controversies. Aside from state-of-the-art lectures, debates and cases discussion are scheduled with topics such as laparoscopic surgery, challenges in bladder cancer diagnosis and bladder preservation.

Also programmed throughout the five-day meeting are interactive courses organised by the European School of Urology. The courses are limited to 100 participants; registration is necessary.
-end-
Press representatives are invited to attend the press programme, including the EAU press conference, 'EAU TV', a new media initiative including 7 panel discussions with experts which are posted online, and the Meet-the-Expert sessions, this year with Profs Abrams, Naber and Albers. For more information please visit www.eaustockholm2009.org.

European Association of Urology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.